SVA - Sinovac Biotech Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.47
0.00 (0.00%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close6.47
Open6.49
Bid0.00 x 800
Ask0.00 x 1100
Day's Range6.28 - 6.58
52 Week Range5.73 - 8.66
Volume0
Avg. Volume3,040
Market Cap640.001M
Beta (3Y Monthly)0.18
PE Ratio (TTM)12.94
EPS (TTM)0.50
Earnings DateJun 1, 2017 - Jun 5, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • Business Wire2 days ago

    Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the Journal of Infectious Disease

    The Sinovac-developed sIPV demonstrates both long-term affordability and accessibility and has the potential to contribute significantly to polio eradication in developing countries and the progress towards a polio-free world. Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the positive results from the Company’s Phase III clinical study of a Sabin strain-based inactivated polio vaccine (sIPV) developed by Sinovac were published in the Journal of Infectious Disease.

  • Business Wire6 days ago

    Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares

    Sinovac Biotech Ltd. (SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an update for shareholders with regards to the exchange (the “Exchange”) of preferred share purchase rights (the “Rights”) for the Company’s Common Shares and Series B Convertible Preferred Shares (the “Exchange Shares”), originally announced on February 22, 2019, by press release. On April 4, 2019, the Eastern Caribbean Supreme Court, Court of Appeal issued an order that restrains the Company from taking further action under its Rights Agreement, including the distribution of the previously issued Exchange Shares to the holders of valid Rights, until the conclusion of 1Globe Capital, LLC’s appeal of the December 19, 2018 Judgment of the High Court of Justice of Antigua and Barbuda.

  • Business Wire2 months ago

    Sinovac Determines Trigger Event Occurred Under Rights Agreement

    Board of Directors Amends and Restates Rights Agreement and Declares Dividend Distribution of New Preferred Share Purchase Rights. Sinovac Biotech Ltd. (SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that its Board of Directors (the “Board”) determined that certain stockholders became “Acquiring Persons,” as defined in the Company’s Rights Agreement (“Rights Agreement”), prior to the Company’s Annual General Meeting held on February 6, 2018 (the “AGM”).

  • Reuters2 months ago

    Sinovac Biotech activates 'poison pill' defense in rare move

    Sinovac Biotech Ltd, a Nasdaq-listed Chinese vaccine developer, activated a shareholders rights plan on Friday, according to a press release seen by Reuters, the first time a company has used a "poison pill" takeover defense in more than a decade. Sinovac is seeking to defend itself against a group of shareholders, including investment firms 1Globe Capital LLC, Chiangjia Li and OrbiMed Advisors LLC, which own 40 percent of the company. While companies occasionally threaten to use poison pill defenses, they rarely proceed.

  • GlobeNewswire2 months ago

    Nasdaq Halts Sinovac Biotech Ltd.

    NEW YORK, Feb. 22, 2019 -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading was halted today in Sinovac Biotech Ltd. (Nasdaq: SVA) at 16:02:01 p.m. Eastern Time.

  • Can Sinovac Biotech Ltd.’s (NASDAQ:SVA) ROE Continue To Surpass The Industry Average?
    Simply Wall St.3 months ago

    Can Sinovac Biotech Ltd.’s (NASDAQ:SVA) ROE Continue To Surpass The Industry Average?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...

  • Business Wire4 months ago

    Sinovac Comments on Antigua and Barbuda Court Decision Denying 1Globe Capital’s Claim; Current Board Was Validly Elected at Annual General Meeting

    Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the High Court of Justice of Antigua and Barbuda rejected the claim of 1Globe Capital LLC (“1Globe”) for a declaration that an alternative slate of directors had been elected at the Company’s Annual General Meeting in February 2018. The Court’s decision means that the current directors of the Company were validly elected at the Annual General Meeting held in February 2018 (“AGM”) and remain the directors of the Company.

  • Business Wire4 months ago

    Haidian District People’s Court in Beijing Issues Injunction Order Restraining Aihua Pan from Using Business License and Corporate Seal of Sinovac Beijing

    Sinovac Biotech Ltd. (“Sinovac” or the “Company”) announced that the People’s Court in Haidian District, Beijing (the “Court”), has issued an interim injunction order restraining Mr. Aihua Pan from using or authorizing others to use the business license, corporate seal (No.:1101081347485), contract seal and invoice seal of the Company’s subsidiary, Sinovac Biotech Co., Ltd (“Sinovac Beijing”), that were improperly obtained by him.

  • Reuters5 months ago

    BRIEF-Hong Kong High Court Issues Declaratory Orders & Permanent Injunctive Relief In Favor Of Sinovac's Senior Management

    Nov 28 (Reuters) - Sinovac Biotech Ltd: * HONG KONG HIGH COURT ISSUES DECLARATORY ORDERS AND PERMANENT INJUNCTIVE RELIEF IN FAVOR OF SINOVAC’S BIOTECH LTD. SENIOR MANAGEMENT * SINOVAC BIOTECH - PERMANENT ...

  • Business Wire5 months ago

    Hong Kong High Court Issues Declaratory Orders and Permanent Injunctive Relief in Favor of Sinovac’s Biotech Ltd. Senior Management

    Senior management of Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company") and the lawful directors of Sinovac Hong Kong, Mr. Yin Weidong and Ms. Wang Nan (“Lawful Directors”), have been granted declaratory orders and permanent injunctive relief against Mr. Li Pengfei (“Mr. Li”) and Mr. Cao Jianzeng (“Mr. Cao”) by the High Court of the Hong Kong Special Administrative Region (“Hong Kong High Court”). Mr. Li and Mr. Cao have appealed the decision to the Court of Appeals.

  • PR Newswire5 months ago

    Sinovac Reports Unaudited First Half of 2018 Financial Results

    BEIJING , Nov. 8, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China , announced today its ...

  • Business Wire6 months ago

    Sinovac Granted Interim Injunctive Relief Regarding Filings Bearing a Falsified Company Seal and Forged Board Member Signatures

    Senior management of Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company") and the lawful directors of Sinovac Hong Kong (“Lawful Directors”), Mr. Yin Weidong and Ms. Wang Nan, have been granted interim injunctive relief against Mr. Li Pengfei (“Mr. Li”) and Mr. Cao Jianzeng (“Mr. Cao”) by the High Court of the Hong Kong Special Administrative Region (“Hong Kong High Court”). The interim injunction was granted in the Hong Kong High Court proceedings brought by the Lawful Directors to nullify and remove forged documents that were illegally filed with the Hong Kong Companies Registry (“Companies Registry”) in respect of Sinovac Biotech (Hong Kong) Limited (“Sinovac HK”).

  • PR Newswire6 months ago

    U.S. District Court in Massachusetts Denies 1Globe's Motion for Preliminary Injunction to Enjoin Sinovac's Issuance of Shares

    BEIJING , Oct. 17, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:  SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China , today announced ...

  • Reuters6 months ago

    BRIEF-Sinovac Biotech Says Commences Legal Proceedings To Nullify Filings Bearing A Falsified Company Seal And Forged Board Member Signatures

    Oct 15 (Reuters) - Sinovac Biotech Ltd: * SINOVAC COMMENCES LEGAL PROCEEDINGS TO NULLIFY FILINGS BEARING A FALSIFIED COMPANY SEAL AND FORGED BOARD MEMBER SIGNATURES * SINOVAC BIOTECH-ALSO PETITIONED IN ...

  • Business Wire6 months ago

    Sinovac Commences Legal Proceedings to Nullify Filings Bearing a Falsified Company Seal and Forged Board Member Signatures

    Senior management of Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company") and the lawful directors of Sinovac Hong Kong have commenced legal proceedings in the High Court of the Hong Kong Special Administrative Region to nullify and remove forged documents that were illegally filed with the Hong Kong Companies Registry in respect of Sinovac Biotech (Hong Kong) Limited (“Sinovac HK”) and with the Industry and Commerce Bureau of Beijing in respect of Sinovac Biotech Co., Ltd. (“Sinovac Beijing”). In addition, in the High Court of Justice in Antigua and Barbuda, the Company has petitioned for 1Globe Capital LLC (“1Globe”) to be restrained from making any attempt to take control of the company or in any other way undermine the court’s authority in the existing litigation between 1Globe and the Company.

  • Reuters6 months ago

    BRIEF-Sinovac Biotech Says Unauthorized Changes Have Been Made To The Hong Kong Companies Registry

    Oct 10 (Reuters) - Sinovac Biotech Ltd: * BECAME AWARE ON OCTOBER 8 THAT UNAUTHORIZED CHANGES HAVE BEEN MADE TO THE HONG KONG COMPANIES REGISTRY FOR SINOVAC BIOTECH LIMITED * UNAUTHORIZED CHANGES HAVE ...

  • Business Wire6 months ago

    Sinovac Comments on Unauthorized Use of Falsified Sinovac Hong Kong’s Company Seal and Subsidiary Board Member Signatures

    Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), became aware Monday October 8, 2018 that unauthorized changes have been made to the Hong Kong Companies Registry for Sinovac Biotech (Hong Kong) Limited (“Sinovac HK”) and that unauthorized changes have been made to the Industry and Commerce Bureau of Beijing for Sinovac Biotech Co., Ltd. (“Sinovac Beijing”).

  • PR Newswire7 months ago

    DOJ Closes Investigation of Sinovac

    BEIJING , Sept. 17, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China , today announced ...

  • Benzinga8 months ago

    The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 20) Avanos Medical Inc (NYSE: AVNS ) Becton Dickinson and Co (NYSE: ...

  • PR Newswire8 months ago

    SEC Concludes Investigation of Sinovac

    BEIJING , Aug. 20, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China , today announced ...

  • PR Newswire9 months ago

    Sinovac Raises $86.73 Million Through Private Placement Transaction

    BEIJING, July 3, 2018 /PRNewswire/ --Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it has completed a private placement of its common shares (a "private investment in public equity," or "PIPE") with private investors Vivo Capital and Advantech Capital. Sinovac will receive gross proceeds of $86.73 million. The proceeds will be used to increase the Company's capabilities in research relating to quality control and to build additional production facilities to support the development and commercialization of sIPV-based combination vaccine and other new vaccine projects.

  • PR Newswire10 months ago

    Sinovac Files Motion for Summary Judgment on Rights Agreement in Delaware Chancery Court

    BEIJING, June 26, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it has filed a motion for partial summary judgment in Delaware Chancery Court. The motion introduces recently obtained information showing that the Sinobioway Consortium, led by Sinobioway Biomedicine Co., Ltd. ("Sinobioway"), a minority shareholder of the Company's controlled Chinese subsidiary, Sinovac Biotech Co., Ltd. ("Sinovac Beijing"), and a group of Sinovac's shareholders led by 1Globe and OrbiMed (the "Dissident Shareholders") reached an agreement, arrangement or understanding before the Company's annual general meeting held on February 6, 2018 (the "AGM"). Prior to the AGM, the Sinobioway Consortium and the Dissident Shareholders agreed to appear at the AGM to nominate and to vote for new directors controlled by Sinobioway or the Dissident Shareholders.

  • Is Sinovac Biotech Ltd’s (NASDAQ:SVA) PE Ratio A Signal To Buy For Investors?
    Simply Wall St.10 months ago

    Is Sinovac Biotech Ltd’s (NASDAQ:SVA) PE Ratio A Signal To Buy For Investors?

    Sinovac Biotech Ltd (NASDAQ:SVA) trades with a trailing P/E of 18.8x, which is lower than the industry average of 27.5x. While this makes SVA appear like a great stock toRead More...

  • PR Newswire10 months ago

    Sinovac Biotech Relaunches Company Website

    BEIJING , June 11, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:  SVA ) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced ...